Objective: To investigate the clinical characteristics, diagnosis and treatment methods of patients with myeloid sarcoma(MS)． Methods: The clinical data, laboratory examination, clinical pathology and treatment methods of 15 patients with MS treated in the First Affiliated Hospital of Wannan Medical College from June 2012 to January 2020 were retrospectively analyzed.
Results: Among the 15 cases of MS, including eight males and seven females, the middle age of patients were 53（19 to 72）. Among the 15 patients with MS, 4 showed solitary MS, while 11 showed secondary MS. Immunohistochemical results showed that MPO+（12/15）、CD68+（3/6）、Lys+（3/3）、CD34+（6/14）、TdT+（0/9）、CD43+（13/13）、CD117+（6/10）、CD15+（7/10）、CD3+（1/15）、CD20+（0/15）. 6 of 13 patients were survival till follow-up date．The median overall survival (OS) time was 16 months (1-88 months)．Conclusion: Myeloid sarcoma is rare and often secondary from acute myeloid leukemia(AML) and chronic myeogenous leukemia(CML). Isolated MS can easily be misdiagnosed as lymphoma. Treatment response should be evaluated in combination with bone marrow examination, PET/CT and other imagines．Systematic chemotherapy and hematopoietic stem cell transplantation are the main method to treat MS.
题目: 髓系肉瘤患者的临床特点分析.
目的: 探讨髓系肉瘤(MS)患者的临床表现、诊断及治疗方法，以期提高对MS的认识.
方法: 对本院2012年6月-2020年1月就诊的15例髓系肉瘤患者的临床资料、实验室及病理学结果、治疗方案进行回顾性分析.
结果: 15例髓系肉瘤患者中，男性8例、女性7例，中位年龄53（19-72）岁。孤立性MS患者 4例，继发于其它血液肿瘤的MS患者 11 例；免疫组织化学结果显示，肿瘤细胞MPO（12/15）、CD68（3/6）、Lys（3/3）、CD34（6/14）、TdT（0/9）、CD43（13/13）、CD117（6/10）、CD15（7/10）、CD3（1/15）、CD20（0/15）均阳性。13例可随访的患者中，死亡7例，6例生存，中位生存时间16（1-88）个月.
结论: 髓系肉瘤患者少见于临床，往往多继发于急性髓系白血病（AML）、慢性髓系白血病（CML）；孤立性MS容易被误诊为淋巴瘤。疗效评价应结合骨髓学及PET/CT等影像学进行综合评估，系统性化疗及造血干细胞移植是目前治疗该病的主要手段.